دورية أكاديمية
Immunohistochemical expression of excision repair cross-complementing 1 (ERCC1) in non-small-cell lung cancer: Implications for patient outcome
| العنوان: | Immunohistochemical expression of excision repair cross-complementing 1 (ERCC1) in non-small-cell lung cancer: Implications for patient outcome |
|---|---|
| المساهمون: | Uludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı., orcid:0000-0002-9732-5340, Çubukçu, Erdem, Ölmez, Ömer Fatih, Saraydaroǧlu, Özlem, Akçalı, Ünsal, Kanat, Özkan, Kurt, Ender, Evrensel, Türkkan, Manavoǧlu, Osman, AAJ-1027-2021, AAH-9701-2021, 53986153800, 26435400000, 15074395500, 16027743900, 55881548500, 7006207332, 6603942124, 6602587152 |
| بيانات النشر: | Springer International Publishing AG |
| سنة النشر: | 2011 |
| المجموعة: | Açık Erişim@BUU (Bursa Uludağ Üniversitesi) |
| مصطلحات موضوعية: | Oncology, Non-small-cell lung cancer, Excision repair cross-complementing 1, Immunohistochemistry, Prognosis, Dna-repair, Chemotherapy, Messenger-RNA, Biomarkers, Resistance, Therapy, Gene, Adult, Aged, Antineoplastic agents, Carcinoma, non-small-cell lung, adjuvant, Cisplatin, Disease-free survival, DNA-binding proteins, Endonucleases, Female, Humans, Lung neoplasms, Male, Middle aged, DNA Repair, Value of Repair, Ribonucleotide Reductases |
| الوصف: | The identification of novel prognostic markers may help to better assess survival probability in different subgroups of patients with non-small-cell lung cancer (NSCLC) and to tailor treatment according to the molecular profile of the tumour. We sought to examine whether the immunohistochemical expression of excision repair cross-complementing 1 (ERCC1), an essential component of the nucleotide excision repair pathway, may predict prognosis in NSCLC. Formalin-fixed paraffin-embedded tumour samples from 44 Turkish patients with NSCLC treated by adjuvant platinum-based chemotherapy were included in the study. Immunohistochemical expression levels of ERCC1 were correlated with clinical outcomes by Kaplan-Meier curves and multivariable Cox proportional hazards regression analysis. A total of 29 patients had ERCC1-negative tumours while 15 had ERCC1-positive tumours. The mean progression-free survival (PFS) was significantly lower in patients with ERCC1-positive tumours (13 +/- 2 months) than in those with ERCC1-negative tumours (27 +/- 5 months, p < 0.05). Similarly, the mean overall survival (OS) was significantly lower in patients with ERCC1-positive tumours (20 +/- 3 months) than in those with ERCC1-negative tumours (33 +/- 5 months, p < 0.05). After allowance for potential confounders, Cox regression analysis demonstrated that ERCC1 expression was significantly associated with both PFS and OS (both p < 0.05). This study provides support for the prognostic value of ERCC1 immunohistochemical expression in patients with NSCLC treated by adjuvant platinum-based chemotherapy. If independently confirmed, these findings may improve prognostic stratification in this group of patients. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1699-048X 1699-3055 |
| العلاقة: | Makale - Uluslararası Hakemli Dergi; Clinical and Translational Oncology; Çubukçu, E. vd. (2011). ''Immunohistochemical expression of excision repair cross-complementing 1 (ERCC1) in non-small-cell lung cancer: Implications for patient outcome''. Clinical and Translational Oncology, 13(11), 826-830.; https://doi.org/10.1007/s12094-011-0741-7Test; https://link.springer.com/article/10.1007/s12094-011-0741-7Test; http://hdl.handle.net/11452/24546Test; 000297518700012; 2-s2.0-84856052532; 826; 830; 13; 11 |
| DOI: | 10.1007/s12094-011-0741-7 |
| الإتاحة: | https://doi.org/10.1007/s12094-011-0741-7Test http://hdl.handle.net/11452/24546Test |
| حقوق: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.8CE048EA |
| قاعدة البيانات: | BASE |
| تدمد: | 1699048X 16993055 |
|---|---|
| DOI: | 10.1007/s12094-011-0741-7 |